| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
FL118-14-Propanol targets multiple oncogenic proteins. Similar to its parent compound FL118, it selectively inhibits key anti-apoptotic proteins including survivin, Mcl-1, XIAP, and cIAP2. It also targets the DDX5/p68 oncoprotein, promoting its degradation through ubiquitin-mediated pathways, which disrupts oncogenic signaling cascades critical for tumor growth and survival. Additionally, it is a potential topoisomerase I inhibitor and induces pro-apoptotic proteins such as Bax and Bim.
|
|---|---|
| ln Vitro |
FL118-14-Propanol exhibits higher cytotoxicity in colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC) models compared to the parent compound FL118. Studies on CRC cell lines demonstrated that treatment with FL118-14-Propanol resulted in a marked decrease in cell viability with IC₅₀ values in the nanomolar range. The compound induces G2/M phase arrest and apoptosis in cancer cells. The 1-propanol structural modification enhances solubility, which may contribute to improved in vitro potency.
|
| ln Vivo |
ADC molecules synthesized using FL118-14-Propanol have shown good anti-tumor effects in mouse models. In animal models of pancreatic ductal adenocarcinoma (PDAC), administration of FL118-14-Propanol led to significant tumor regression compared to control groups. The efficacy is dependent on DDX5 expression levels in determining treatment response. The compound shows promise in overcoming drug resistance and enhancing tumor selectivity.
|
| Enzyme Assay |
Based on its parent compound FL118, it is understood that FL118-14-Propanol likely binds directly to DDX5/p68 protein with high affinity, inducing its degradation through the ubiquitin-proteasome pathway. This mechanism of action is inferred from FL118 studies and has not been independently validated for this derivative.
|
| Cell Assay |
For in vitro studies, FL118-14-Propanol is typically dissolved in DMSO as a stock solution (e.g., 100 mg/mL in DMSO). The working solution can be prepared by diluting the stock in appropriate cell culture media. For cell viability assays, cancer cells are seeded in 96-well plates and treated with various concentrations of the compound for 24-72 hours, followed by MTT or similar assays to determine IC₅₀ values. Cell cycle analysis by flow cytometry and apoptosis detection by Annexin V staining can be performed to evaluate the mechanism of action.
|
| Animal Protocol |
For in vivo administration, FL118-14-Propanol can be formulated using various injection formulations. Common formulations include: (1) DMSO : Tween 80 : Saline = 10 : 5 : 85; (2) DMSO : PEG300 : Tween 80 : Saline = 10 : 40 : 5 : 45; (3) DMSO : Corn oil = 10 : 90. For oral administration, the compound can be suspended in 0.5% CMC Na (carboxymethylcellulose sodium) or dissolved in PEG400. The ADC molecules synthesized using FL118-14-Propanol are typically administered via intravenous injection. Dosing frequency and duration vary depending on the specific study design.
|
| ADME/Pharmacokinetics |
No direct pharmacokinetic data for FL118-14-Propanol (absorption, distribution, metabolism, excretion, half-life, oral bioavailability) were reported in the available literature. However, the 1-propanol structural modification is intended to enhance solubility and improve pharmacokinetic properties compared to the parent compound FL118. ADC molecules synthesized using FL118-14-Propanol have demonstrated good in vivo anti-tumor effects, suggesting favorable PK profiles.
|
| Toxicity/Toxicokinetics |
No direct toxicity data for FL118-14-Propanol (LD₅₀, organ toxicity, etc.) were reported in the available literature. The product is for research use only and should be handled with appropriate safety precautions. Based on the parent compound FL118, the derivative is likely to have cytotoxic effects and should be considered hazardous. Standard laboratory safety practices including the use of personal protective equipment (gloves, lab coat, eye protection) should be followed when handling this compound.
|
| References | |
| Additional Infomation |
FL118-14-Propanol is a derivative of the potent anticancer agent FL118, structurally modified with a 1-propanol moiety to enhance solubility and pharmacokinetic properties. It is a cytotoxic camptothecin derivative and a potential topoisomerase I inhibitor with potential antitumor activity, which can be used in the synthesis of ADC (antibody-drug conjugate) compounds. The compound has a molecular formula of C₂₄H₂₂N₂O₇ and a molecular weight of 450.44 g/mol. Purity is typically ≥98%. The compound should be stored as a powder at -20°C (stable for up to 3 years) or at 4°C (stable for up to 2 years), protected from light and moisture. Solubility: Soluble in DMSO (80-100 mg/mL). Reference: WO2023143208 A1.
|
| Molecular Formula |
C24H22N2O7
|
|---|---|
| Molecular Weight |
450.440686702728
|
| CAS # |
2821768-98-1
|
| PubChem CID |
164872962
|
| Appearance |
Light yellow to yellow solid powder
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
33
|
| Complexity |
932
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
O1C([C@](CC)(C2C=C3C4C(=C(CCCO)C5C=C6C(=CC=5N=4)OCO6)CN3C(C=2C1)=O)O)=O
|
| Synonyms |
FL 118-14-Propanol; FL-118-14-Propanol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~33.3 mg/mL (74.0 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2201 mL | 11.1003 mL | 22.2005 mL | |
| 5 mM | 0.4440 mL | 2.2201 mL | 4.4401 mL | |
| 10 mM | 0.2220 mL | 1.1100 mL | 2.2201 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
